GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Cyclically Adjusted FCF per Share

Heidelberg Pharma AG (XTER:HPHA) Cyclically Adjusted FCF per Share : €-0.63 (As of Aug. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Heidelberg Pharma AG's adjusted free cash flow per share for the three months ended in Aug. 2024 was €-0.130. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.63 for the trailing ten years ended in Aug. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 8.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 17.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Heidelberg Pharma AG was 24.40% per year. The lowest was 8.80% per year. And the median was 15.40% per year.

As of today (2024-12-14), Heidelberg Pharma AG's current stock price is €2.45. Heidelberg Pharma AG's Cyclically Adjusted FCF per Share for the quarter that ended in Aug. 2024 was €-0.63. Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF of today is .


Heidelberg Pharma AG Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Heidelberg Pharma AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Cyclically Adjusted FCF per Share Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.29 -0.87 -0.79 -0.78 -0.66

Heidelberg Pharma AG Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 -0.66 -0.64 -0.62 -0.63

Competitive Comparison of Heidelberg Pharma AG's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Cyclically Adjusted Price-to-FCF falls into.



Heidelberg Pharma AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Heidelberg Pharma AG's adjusted Free Cash Flow per Share data for the three months ended in Aug. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Aug. 2024 (Change)*Current CPI (Aug. 2024)
=-0.13/126.1978*126.1978
=-0.130

Current CPI (Aug. 2024) = 126.1978.

Heidelberg Pharma AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201411 -0.058 99.543 -0.074
201502 -0.103 99.217 -0.131
201505 -0.150 100.417 -0.189
201508 -0.112 100.617 -0.140
201511 -0.178 99.717 -0.225
201602 -0.128 99.317 -0.163
201605 -0.107 100.617 -0.134
201608 -0.137 101.017 -0.171
201611 -0.188 100.517 -0.236
201702 -0.153 101.217 -0.191
201705 -0.142 101.817 -0.176
201708 -0.070 102.617 -0.086
201711 -0.208 102.117 -0.257
201802 -0.121 102.317 -0.149
201805 -0.054 103.917 -0.066
201808 -0.097 104.517 -0.117
201811 -0.118 104.217 -0.143
201902 -0.120 103.817 -0.146
201905 -0.104 105.418 -0.125
201908 -0.014 106.018 -0.017
201911 -0.099 105.318 -0.119
202002 -0.174 105.618 -0.208
202005 -0.131 106.018 -0.156
202008 -0.187 106.018 -0.223
202011 -0.142 105.018 -0.171
202102 -0.223 107.018 -0.263
202105 -0.224 108.170 -0.261
202108 -0.192 109.118 -0.222
202111 -0.217 110.173 -0.249
202202 -0.192 111.754 -0.217
202205 0.396 115.760 0.432
202208 -0.212 116.709 -0.229
202211 -0.169 119.872 -0.178
202302 -0.236 121.454 -0.245
202305 -0.169 122.824 -0.174
202308 -0.182 123.878 -0.185
202311 -0.155 123.668 -0.158
202402 -0.240 124.511 -0.243
202405 -0.133 125.776 -0.133
202408 -0.130 126.198 -0.130

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Heidelberg Pharma AG  (XTER:HPHA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Heidelberg Pharma AG Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG Business Description

Industry
Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Walter Miller Board of Directors
Dr. Georg F. Baur Supervisory Board
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines